MYC and colorectal carcinoma: Heterogenous CRC has been recently classified into four consensus molecular subtypes (CMS1-4) with distinguishing features: CMS1 (MSI, immune), hypermutated, microsatellite unstable and strong immune activation; CMS2 (canonical), epithelial, marked WNT and MYC signaling activation; CMS3 (metabolic), epithelial and with evident metabolic dysregulation; and CMS4 (mesenchymal), characterized by transforming growth factor– β activation, stromal invasion and angiogenesis [46].